Recursion · 2 weeks ago
Associate Principal Computational Biologist, Neuroscience
New York, NY+1 more
Full-time
Hybrid
Lead/Staff
$221K/yr - $243K/yr
5+ years expRecursion is a clinical-stage TechBio company focused on advancing drug discovery through innovative data science. The Associate Principal Computational Biologist will support partnership preclinical drug programs in neuroscience by designing and executing analyses to validate targets and develop novel therapeutic programs.
Artificial Intelligence (AI)BiotechnologyPharmaceuticalSoftwareMachine LearningTherapeutics
Responsibilities
Deliver biological insights on therapeutic candidates and disease biology from the analysis of high-dimensional (phenomics, transcriptomics, proteomics, patient-derived) datasets that support clinical development planning
Evaluate the biological and molecular evidence for therapeutic hypotheses and accelerate drug program progression into the clinic
Synthesize diverse datasets (internal and external) to generate and evaluate hypotheses for drug discovery, biomarker development, mechanism of action and target population identification
Present data analysis to decision makers and stakeholders in a clear and compelling way that drives toward getting medicines to patients
Assess new data sources, develop and scale new analysis methods, and support key program decisions with the ultimate goal of bringing life-changing therapies to patients at unprecedented speed
Industrialize analysis approaches to not only solve for the current project, but also to accelerate future projects and scale the impact that we can have
Collaborate cross-functionally with Recursion’s data science, biology, medicinal chemistry, and platform, teams to further advance Recursion’s ability to interpret and translate large-scale data assets into therapeutic programs
Qualification
Required
PhD in a relevant field (computational biology, systems biology, bioinformatics, neuroscience, etc.) with a very strong computational focus and 5+ years of experience in biotech or pharma industry OR MS in a relevant field
Experience applying computational methods (including probabilistic, statistical, and/or machine learning techniques) to analyze and integrate matched human clinical and molecular data in a high-level programming language such as Python or R
Deep expertise in the analysis and data integration of one or more ‘omics data modalities (phenomics, transcriptomics, proteomics, genomics) and/or human clinical data
Exceptional data visualization skills
Excellent cross-functional communication skills, including an ability to explain complex scientific concepts to a variety of audiences using a combination of plots, documents, and presentations
Preferred
Strong understanding of patient genetics and historical druggability of disease-relevant pathways, including experience working with patient data
Experience in efficiently advancing drug programs from proof of concept and into clinical development
Experience with neuroscience clinical trial biomarker analysis
Experience working as part of partnerships or client facing (consulting) teams
Benefits
Annual bonus
Equity compensation
Comprehensive benefits package
Office-based, hybrid role
Expected to work in the office at least 50% of the time
Company
Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives.
501-1000 employees
H1B Sponsorship
Recursion has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
85%
Represents job field similar to this job
Engineering and Development
Accounting and Finance
Management and Executive
Legal and Compliance
Trends of Total Sponsorships
*2025 (6)
2024 (6)
2023 (5)
2022 (2)
2021 (1)
Funding
Current Stage
Public CompanyTotal Funding
$865.38MKey Investors
NVIDIAKinnevikLeaps by Bayer
2024-06-26Post Ipo Equity· $200M
2023-07-12Post Ipo Equity· $50M
2022-10-25Post Ipo Equity· $150M
Leadership Team
Najat Khan
Chief Executive Officer & President | Member, Board of Directors
Ben Mabey
Chief Technology Officer
Recent News
2026-08-12
2026-08-10
2026-08-10
Company data provided by crunchbase